Importantly, both clinical and proteomic data revealed patients harbored both EGFR mutations and amplifications exhibited higher values of the tumor proliferative marker Ki67, which implied the possible association between fast tumor cell proliferation and poor prognosis of these patients. This evidence concerns the gene EGFR and neoplasm.